Ragnar

Ragnar is Elixir 2.0's branded 20 mg vial of retatrutide (LY3437943), an investigational triple receptor agonist studied against GIP, GLP-1, and glucagon receptors. Compound overview: Retatrutide has been studied for effects on body weight and cardiometabolic measures in adults with obesity. A 2023 Phase 2 randomized, double-blind, placebo-controlled trial (Jastreboff et al., N Engl J Med. 2023;389:514–526) evaluated once-weekly arms over 48 weeks. Third-party tested. Certificate of Analysis (COA) available upon request. Storage: Refrigerate 2°C–8°C. Protect from light. Do not freeze. For laboratory research use only. Not for human consumption, clinical use, diagnostic use, or veterinary use. Not a drug, food, or cosmetic. Sold as a lyophilized research material in a sealed vial. Buyer is responsible for lawful handling, storage, and use.